Conditions

High linoleic acid level could reduce type 2 risk by 43 percent, new study found.

Patients with type 2 diabetes not responding to basal insulin therapy alone may see glycemic improvement with a GLP-1 receptor agonist.

New study finds incidence of thyroid disorders in people with diabetes no higher than than those without.

Canagliflozin may reduce the risk of major cardiovascular complication, but amputation risk is increased.

Second-line treatment is often initiated without evidence of recommended use of first-line treatment.

Recent meta-analysis conducted to address ideal amount of dietary carbohydrates in the management of T2DM.

Trial shows HbA1c reduced, hypoglycemia and DKA similar across study participants.

By Guest Writer David Kliff, Diabetic Investor: As we were getting ready to disembark the plane when it arrived in Lisbon I asked a long-term consultant to the diabetes industry why he comes to EASD. “I like to come here because what they have here will show up in our country in two years” was his response. Given what we witnessed at EASD there isn’t much to look forward to in 2019.

Received a phone call from someone I know. Has not yet come in for a visit. Just called to see if she qualified to come in for a visit. Woman, 68 years of age, denies history of diabetes, hypertension or other health problems, except being overweight. She stated, “Last year my weight was up. I went on a diet because my triglycerides were high, in the 600’s, but they came down to 140’s when I lost 30 pounds last year. I think I gained back about 10 pounds so that would be about 155 pounds now.” I asked her if she’s weighed herself. She said, no, not since I got off the program, but when I was on the program, I weighed daily. You know, I had holidays, travel, I was with a group, paid for the food, so ate what they all ate, then I just couldn’t get back on track.”

Trial results promising, but DKA still a concern with use of new once-daily pills.